08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

OMS201: Phase I/II data

A double-blind, placebo-controlled Phase I/II trial in 24 patients undergoing ureteroscopy for removal of ureteral or renal stones showed that both concentrations of OMS201 added to standard irrigation solution were well tolerated with no treatment-related...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Tracking Omeros

Tracking Omeros In its S-1 filing updated Sept. 16, IPO candidate Omeros Corp. estimates the fair value of its shares, based on factors including results from operations, market value of a comparison group of publicly...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

OMS201: Phase I data

In a double-blind, vehicle-controlled Phase I trial in patients undergoing endoscopic removal of urinary stones, OMS201 did not produce serious adverse events. Also, plasma levels of the active ingredients were minimal and in most cases...
07:00 , May 26, 2008 |  BC Week In Review  |  Clinical News

OMS201: Phase I started

Omeros began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate OMS201 in at least 24 patients undergoing unilateral ureteroscopic removal of urinary stones. Omeros Corp. , Seattle, Wash.   Product: OMS201   Business: Diagnostic...